A POC Clinical Trial for PTSD with a First-In-Class Vasopressin 1a Receptor Antagonist

Abstract

In this reporting period, year 5 of the project, the major milestones met included obtaining renewal from the responsible local Institutional Review Board (IRB) and the Human Research Protections Office (HRPO) and the DSMB. No new patients were enrolled in year 5 with a total of 33 patients randomized to date. Azevan received a 3 month extension in order to lock database, unblind, and perform analyses.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1123824

Entities

People

  • JoAnn Difede
  • Neal G. Simon

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Clinical Trials
  • Contracts
  • Covid-19
  • Data Analysis
  • Data Management
  • Databases
  • Electronic Mail
  • Health Services
  • Institutional Review Board
  • Maryland
  • Medical Personnel
  • New York
  • Patent Applications
  • Personnel Management
  • Physicians
  • Pituitary And Hypothalamic Hormones And Analogues
  • Professional Development
  • Quality Of Life
  • Technology Transfer
  • Test And Evaluation
  • Therapy
  • Training

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.